Zimmer Biomet’s (ZBH) “Hold” Rating Reiterated at Truist Financial

Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating reaffirmed by analysts at Truist Financial in a report released on Monday,Benzinga reports. They currently have a $113.00 price target on the medical equipment provider’s stock, down from their prior price target of $118.00. Truist Financial’s price objective indicates a potential upside of 12.11% from the company’s current price.

A number of other brokerages also recently issued reports on ZBH. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Friday. Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, JMP Securities reiterated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 0.1 %

Zimmer Biomet stock opened at $100.79 on Monday. The business has a 50-day simple moving average of $107.34 and a two-hundred day simple moving average of $108.07. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market cap of $20.07 billion, a P/E ratio of 22.65, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet has a 52-week low of $99.93 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the company posted $2.20 EPS. Analysts predict that Zimmer Biomet will post 8.25 EPS for the current year.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the business. Dunhill Financial LLC lifted its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the period. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the third quarter worth about $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet during the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co acquired a new position in Zimmer Biomet in the fourth quarter valued at approximately $39,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.